IDE and early-onset autosomal dominant Alzheimer disease: Insulin-degrading enzyme (IDE) is an attractive target [1,2] for the development of novel therapeutic strategies for type 2 diabetes (T2D) and Alzheimer’s disease (AD), because it degrades amylin [1], which self-assembles to form assemblies that are toxic to the insulin-producing pancreatic β-cells [3] and the amyloid-β protein (Aβ) [2,4], which aggregates to form neurotoxic oligomers [5].